ArticleGalen medical journal2024
Incidence of Malignancy and Risk Factors Associated with Kidney Transplant Patients.
Article in Galen medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence and risk factors associated with the development of post-transplant malignancies contributes to increased morbidity among kidney transplant recipients were examined in this study. MATERIALS AND
methodsA retrospective cross-sectional analysis was conducted to evaluate the medical records of all kidney transplant recipients at Urmia Imam Khomeini Hospital from January 2000 to December 2020. Patients were stratified into two groups based on the presence or absence of post-transplant malignancy. Demographic data, comorbidities, cancer history, and immunosuppression regimens were collected and compared between the groups. Statistical significance was determined using appropriate tests, including the t-test, Mann-Whitney test, Pearson chi-square test, and Fisher exact test. All analyses were performed using SPSS 21, and a P-value of less than 0.05 was considered statistically significant.
resultsOf the 4070 kidney transplant recipients, 3042 (74.7%) were male and 1028 (25.3%) were female. The mean age at malignancy diagnosis was 53.78 years (standard deviation ± 14.24). The overall incidence of post-transplant malignancy was 9.6% per 1,000 patients (95% confidence interval: 9.6-13.2). Incidence rates varied significantly by age group: 4.6% for those younger than 30, 7.6% for those aged 30-50, and 29.3% for those older than 50 (P0.001). A small percentage of patients (n=3, 7.7%) required the addition of antithymocyte globulin (ATG) to their primary immunosuppression regimen. The most commonly used immunosuppressive regimens were prednisolone in combination with either sandimune and azathioprine or sandimune and cellcept, employed in 35.9% of patients. The most common underlying causes of kidney failure were glomerulonephritis (GN) and hypertension (HTN), accounting for 38.5% and 35.9% of cases, respectively.
conclusionKidney transplant recipients demonstrated a higher incidence of post-transplant malignancies. Male sex, older recipient age, and a history of underlying diseases were identified as significant risk factors for malignancy development. The primary cause of kidney failure among the patients was GN, followed by HTN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.